Today, the National Institute of Clinical Excellence (NICE) released a revised preliminary recommendation on the use of Victoza (liraglutide) for patients with type 2 diabetes, following a second appraisal committee meeting held in April. Final guidance is expected as early as October this year.
Victoza is a once-daily injectable human GLP-1 analogue licensed in Europe, the US, Japan and India. It has been available in the UK since July 2009 for people with type 2 diabetes in combination with oral anti-diabetic tablets.
The newly revised preliminary recommendation maintains the positioning of liraglutide issued by NICE in February 2010. It also includes a recommendation that liraglutide 1.2 mg daily is a clinically and cost-effective treatment option, for use in combination with one oral anti-diabetic tablet (metformin or a sulphonylurea) for treatment in people with type 2 diabetes if:
- they are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
- they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.
We are very pleased that NICE has recognised the potential benefits liraglutide can provide to people with type 2 diabetes with its reissued preliminary recommendation which now allows for the use of liraglutide 1.2 mg in combination with one anti-diabetic tablet,” said Viggo Birch, Managing Director, Novo Nordisk Limited.
Novo Nordisk will continue dialogue with NICE regarding patient groups that could benefit from liraglutide 1.8mg and to support the use of liraglutide in line with the licence it was granted in June 2009 by the European Medicines Agency (EMA formerly EMEA).